Advertisement

The Bone Pathway: 223Ra-Dichloride

  • Laura EvangelistaEmail author
  • Alessandra Zorz
Chapter

Abstract

Several beta-emitting radiopharmaceuticals, including 89Sr-chloride, 186Re-hydroxyethylidene diphosphonate, and 153Sm-ethylene diamine tetramethylene phosphonate, have been developed for palliation of bone pain due to metastases. 223Ra dichloride is a novel bone-seeking alpha emitter used for treatment of CRPC in patients with bone metastases. It is a calcium-mimetic solution that selectively targets area of increased bone turnover in bone metastases. First clinical studies with 223Ra started in 2012. This chapter aims to describe the employment of 223Ra-dichloride in clinical setting, by analyzing the different clinical trials and future perspectives for this targeted nuclear medicine therapy.

Keywords

223Ra-Dichloride Pharmacokinetic Biodistribution Phase I Phase II Phase III Prostate cancer Scintigraphy Radiation protection Bone metastases 

Abbreviations

153Sm

Samarium-153

186Re

Rhenium-186

223Ra

Radium-223

89Sr

Strontium-89

ALARA

As low as reasonably achievable

ALP

Alkalinephosphate

ALSYMPCA

ALpharadin in SYMPtomatic Prostate CAncer

CRPC

Castrate-resistant prostate cancer

CT

Computed tomography

EBRT

External beam radiotherapy

Gy

Gray

LET

Linear energy transfer

MBq

MegaBequerel

MDP

Methyl disphosphonate

Mev

Megaelectronvolt

mSv

Milli-sievert

NIST

National Institute of Standard and Technology

PET

Positron emission tomography

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.CrossRefGoogle Scholar
  2. 2.
    Carrasquillo JA, O’Donoghue JA, Pandit-Taskar N. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant-metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2003;40:1384–93.CrossRefGoogle Scholar
  3. 3.
    Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8:587–94.CrossRefGoogle Scholar
  4. 4.
    Nilsson SL, Larsen RH, Foss SD, et al. First clinical experience with a-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451–9.CrossRefGoogle Scholar
  5. 5.
    Nilsson S, Strang P, Aksnes A, et al. A randomized, dose-response, multicentre phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678–86.CrossRefGoogle Scholar
  6. 6.
    Parker C, Pascoe S, Chodacki A, et al. A randomized. Double-blind, dose-finding, multicenter phase 2 trial or radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63(2):189–97.CrossRefGoogle Scholar
  7. 7.
    Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738–46.CrossRefGoogle Scholar
  8. 8.
    Pacilio M, Ventroni G, Cassano B, et al. A case report of image-based dosimetry of bone metastases with Alpharadin (223Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up. Ann Nucl Med. 2016;30:163–8.CrossRefGoogle Scholar
  9. 9.
    Pacilio M, Ventroni G, De Vincentis G, et al. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride. Eur J Nucl Med Mol Imaging. 2016;43(1):21–33.CrossRefGoogle Scholar
  10. 10.
    Hindorf C, Chittenden S, Aksnes A-K, et al. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun. 2012;33:726–32.CrossRefGoogle Scholar
  11. 11.
    AIFM-AIMN. Linee guida AIFM-AIMN per l’utilizzo terapeutico del 223-Ra. 2014.Google Scholar
  12. 12.
    Stabin S a. Health Phys. 2012;102:271–91.CrossRefGoogle Scholar
  13. 13.
    Nilsson S, Balteskard L, Foss SD, et al. Phase I study of Alpharadin2 (223Ra), and a-emitting bone-seeking agent in cancer patients with skeletalmetastases. Eur J Nucl Med Mol Imaging. 2004;31:S290/no 370 [abstract].Google Scholar
  14. 14.
    Carrasquillo JA, J. A. O’Donoghue, Pandit-Taskar N, et al. Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride in patients with castration resistant prostate cancer (CRPC) metastatic to bone. 46th annu Meet am Soc Clin oncol (aSCo) (June 4–8, Chicago) 2010, abstratc 4680. 2010.Google Scholar
  15. 15.
    Chittenden S, Hindorf C, Parker C, et al. A phase 1, open-label study of the biodistribution, pharmacokinetics, and dosimetry of 223Ra-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases. J Nucl Med. 2015;56:1304–9.CrossRefGoogle Scholar
  16. 16.
    Lassmann M, Nosske D. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging. 2013;40:207–12.CrossRefGoogle Scholar
  17. 17.
    Pacilio M, Cassano B, et al. Gamma camera calibrations for the Italian multicentre study for lesion dosimetry in 223Ra therapy of bone metastases. Phys Med. 2017 Sep;41:117–23.  https://doi.org/10.1016/j.ejmp.2017.04.019.CrossRefPubMedGoogle Scholar
  18. 18.
    Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.CrossRefGoogle Scholar
  19. 19.
    Vogelzang NJ, Coleman RE, Michalski JM, et al. Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial. Clin Genitourin Cancer. 2017;15(1):42–52.e8.CrossRefGoogle Scholar
  20. 20.
    Saad F, Carles J, Gillessen S, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17:1306–16.CrossRefGoogle Scholar
  21. 21.
    Sartor AO, Heinrich D., Mariados N, et al. Radium-223 (Ra-223) re-treatment (Re-tx): first experience from an international, multicenter, prospective study in patients (Pts) with castration-resistant prostate cancer and bone metastases (mCRPC). Genitourinary Cancers Symposium 2016. 2016.Google Scholar
  22. 22.
    Morris MJ, HJ Hammers, Sweeney C, et al. Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): a phase I prostate Cancer clinical trials consortium study. ASCO Annual Meeting 2013. 2013.Google Scholar
  23. 23.
    Wilson JM, Parker C. The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer. Expert Rev Anticancer Ther. 2016;16:911–8.CrossRefGoogle Scholar
  24. 24.
    Dalla Volta A, Formenti A, Berruti A. Higher risk of fragility fractures in prostate cancer patients treated with combined radium-223 and abiraterone: prednisone may be the culprit. Eur Urol. 2019;75(6):894–5.  https://doi.org/10.1016/j.eururo.2019.01.026.CrossRefPubMedGoogle Scholar
  25. 25.
    Dizdarevic S, Petersen PM, Essler M, Versari A, Bourre J-C, la Fougere C, et al. Interim analysis of the REASSURE (Radium-223 alpha emitter agent in non-intervetional safety study in mCRPC population for long-term evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice. Eur J Nucl Med Mol Imaging. 2019;46:1102.  https://doi.org/10.1007/s00259-019-4261-y.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Evangelista L, Zorz A. Re: response assessment of 223Ra treatment: should a fluorocholine PET/CT be performed? Clin Nucl Med. 2018;43(11):867–8.PubMedGoogle Scholar
  27. 27.
    García Vicente AM, Soriano Castrejón Á, Alvarez Cabellos R, Sanchez Gil B, Mohedano Mohedano N. Response assessment of 223Ra treatment: should a fluorocholine PET/CT be performed? Clin Nucl Med. 2017;42(10):761–5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Nuclear Medicine UnitVeneto Institute of Oncology IOV—IRCCSPaduaItaly
  2. 2.Medical Physic UnitVeneto Institute of Oncology IOV—IRCCSPaduaItaly

Personalised recommendations